Praxis Precision Medicines, Inc. Q4 FY2025 earnings call

2025 was a remarkable year for Praxis with significant clinical achievements and regulatory advances. 2026 will continue to enhance the clinical portfolio and move towards becoming a commercial company. Next quarter, expect top line results for vormatrigine POWER1 and elsunersen EMBRAVE data. Second half of 2026 expects completion of POWER2 enrollment and EMERALD trial readout. Prelaunch activities for ulixacaltamide and relutrigine include key hires and inventory build. There will be multiple presentations at the American Academy of Neurology (AAN) meeting next quarter on clinical data related to various programs.

Ulixacaltamide

• Absolute terms: 2025 was marked by positive clinical results from the Essential3 program, granted breakthrough designation by the FDA, and submitted an NDA for essential tremor. Revenue potential is over $10 billion.
• Revenue contribution %: N/A (focus on clinical and regulatory advancements rather than direct revenue contribution % at this stage)

Relutrigine

• Absolute terms: Positive data from the EMBOLD study in SCN2A and 8A DEEs, submitted an NDA, potential revenue up to $5 billion.
• Revenue contribution %: N/A

Vormatrigine

• Absolute terms: RADIANT Phase III study showed efficacy, expect top line results from POWER1 in Q2, enrollment in POWER2 to complete by end of year, potential revenue over $4 billion.
• Revenue contribution %: N/A

Elsunersen

• Absolute terms: Favorable FDA meeting, EMBRAVE3 study converting to single-arm baseline controlled, potential revenue over $1 billion.
• Revenue contribution %: N/A

Guidance

• Next quarter, expect top line results for vormatrigine POWER1 (focal epilepsy) and elsunersen EMBRAVE data.
• Second half of 2026, expect completion of POWER2 enrollment and EMERALD trial readout for relutrigine.
• EMERALD trial for relutrigine is expected to serve as the base for an sNDA by next year.
• Plans to hold an R&D Day and a Commercial Day next quarter to discuss clinical programs, preclinical programs, launch strategy, etc.

Question and Answer

• Q: Congrats to the outstanding timing of the filing. Two questions, one directed to Tim and one for Marcio. Tim, walk us through pre-commercial activities and cadence in 2026. Marcio, help understand additional new data at AAN. A: Tim talks about key hires, inventory build, and disease awareness efforts for ulixacaltamide. Marcio mentions there will be 15+ presentations at AAN on the clinical data of the Essential3 program.
• Q: On ulixa, status of alternative titration schedules and commercial prep allocation between relutrigine and ulixa. A: Marcio talks about the FDA's review on the label regarding alternative titration schedules and states that ulixa, with a broader market, will likely get more allocation in commercial prep compared to relutrigine.
• Q: With regard to the POWER3 study, articulate how it helps move towards frontline setting and review timeline for NDAs. A: Marcio discusses the role of the POWER3 study in serving a wider patient population towards the frontline setting and provides considerations on the review timelines for the NDAs, including priority review for relutrigine.
• Q: Clarify response on not asking for priority review for ulixacaltamide, long-term follow-up data at AAN, and pricing strategy. A: Talks about considerations related to the Inflation Reduction Act (IRA), the plan to present long-term data at AAN, and the pricing strategy.
• Q: On relutrigine, how many different DEE patients in Phase III and expectation of efficacy. A: Talks about the diverse patient group in the EMERALD study for relutrigine and the expectation of positive efficacy.
• Q: Follow-up on relutrigine utility across spectrum and vormatrigine RADIANT study data. A: Discusses relutrigine as a tool in the treatment toolbox and the data from the vormatrigine RADIANT study showing patients removing background medications.
• Q: On elsunersen, set expectations for EMBRAVE data and significance of single-arm comparison for EMBRAVE3. A: Talks about the expectations for the EMBRAVE data and the significance of the single-arm comparison in the EMBRAVE3 study.
• Q: On ulixacaltamide ex U.S. efforts and launch trajectory. A: States that the focus is on the U.S. launch and describes a positive launch trajectory.
• Q: On vormatrigine peak revenue potential and utilization impact. A: Talks about retention rates and the revenue potential of vormatrigine.
• Q: Preliminary thoughts on advisory committee for relutrigine or ulixa. A: States there is no indication of an advisory committee for either relutrigine or ulixa at this point.
• Q: Potential synergies between ulixa and relutrigine launches and future launches. A: Discusses infrastructure synergies and future launch synergies between the launches of ulixa and relutrigine.
• Q: Update on essential tremor patient database, EMERALD interim analysis, and FDA publication. A: Talks about the update on the essential tremor patient database, the enrollment pace in the EMERALD trial, and the significance of the FDA publication.
• Q: Increased attention to Cerebrum platform and differentiation of Cerebrum and Solidus. A: Talks about the increased attention to the Cerebrum platform and the differentiation of the Cerebrum and Solidus platforms.
• Q: Distribution of ulixacaltamide prescribers and vormatrigine in focal epilepsy landscape. A: Talks about the distribution of ulixacaltamide prescribers and vormatrigine's position in the focal epilepsy landscape.
• Q: Alternative titration protocol for ulixacaltamide and consideration in standard review. A: Talks about the alternative titration protocol for ulixacaltamide and mentions no major consideration in the standard review related to this protocol